GlobalData on MSN14h
EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial
The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
Based on the interest of principal investigators at additional sites, the Company plans to submit applications to EMA regulators to add 5-10 additional sites in Ireland, Romania, and potentially other ...
Greenwich LifeSciences expands FLAMINGO-01 clinical trial into Europe
Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is ...
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical ...
Morningstar4d
Greenwich LifeSciences Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
news.stocktradersdaily5d
How to Take Advantage of moves in (GLSI)
Buy GLSI near 10.98 target 13.65 stop loss @ 10.95 Details The technical summary data tells us to buy GLSI near 10.98 with an upside target of 13.65. This data also tells us to set a stop loss @ 10.95 ...
Fidelity International6d
Greenwich LifeSciences Inc Ordinary Shares (GLSI)
This stock can be held in an Investment ISA and an Investment Account ...
Briefing.com3d
After Hours Report
After hours report provides a review of the day’s stock market and treasury market session performance with a recap of indices, sector, and industry performance, trends, as well as key news items that ...